CLSD

Clearside Biomedical

CLSD

Attention (50-day avg)0%

Attention rank (50-day avg)#4,774

Bullish sentiment (50-day avg)0%

Price to earnings ratio-0.04

Market capitalization1.3M

Earnings per share-7.05

Dividend yield (TTM)—

Revenue (annual)1.7M

Net income (annual)-34.4M

Social

What share of all stock conversation is about CLSD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Aug 7

The float of Clearside Biomedical, Inc. (CLSD) is being considered for a potential squeeze, with some users wondering if it can move higher soon.
A few users are wondering if it's too late to get in on the stock, or if it's still a good time to buy.
Some users are debating whether to hold onto CLSD or cut losses if the stock stalls, with a few users wondering if a catalyst is needed to move the stock.

Generated by AI

Sentiment

Of the messages about CLSD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	59.93% -22.85
Bearish	—	—	—	40.07% +22.85

Bullish· Nov 24

$CLSD has a high potential for growth, with a target exit point of $10.
Clearside Biomedical, Inc. shareholders will receive all proceeds from the company's sale, net of $3m and legal fees, making a $10 per share price realistic.
The company's recent PR has unlocked a new future for $CLSD, with EU compliance at 47-50% presenting a large addressable gap and potential for significant growth.

Bearish· Jul 23

The company's management team is perceived as incompetent, unable to run a successful pump and dump.
The stock's price is vulnerable to a significant drop, potentially erasing all gains.
The company is likely to cease operations due to royalty obligations, with the possibility of asset sales or strategic alternatives.

Generated by AI

Topics

Of the messages about CLSD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	31.77%
Announcements	—	—	—	39.35%
Controversies	—	—	—	1.08%
Earnings	—	—	—	0%
Macro	—	—	—	27.8%
Technical Analysis	—	—	—	0%

Earnings· May 9

Clearside Biomedical, Inc. (CLSD) reported a loss of $0.62, missing EPS estimates by $0.04.
CLSD will host a Q1 Earnings Call on the day of earnings release, May 9th, before the open.
CLSD's Q1 earnings were released on May 9th, showing a loss of $0.62, which missed consensus estimates.

Announcements· Nov 24

Clearside Biomedical, Inc. (CLSD) has filed a voluntary petition for bankruptcy protection through a Chapter 11 process.
The company plans to pursue a strategic sale of its business through this process.
CLSD shares are trading lower following the announcement, with the company's shares being affected by the bankruptcy filing.

Technical Analysis· Jun 15

$CLSD is holding near the day high on a support line, with potential for further upside.
A cup and handle formation is visible on the daily chart, suggesting a potential continuation of the uptrend.
The stock has a hidden bullish divergence, with lower lows and higher highs, indicating a possible shift in trend.

Generated by AI

Community

Of the messages about CLSD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	65.33%
Newcomers	—	—	100%	34.67%

Regulars· Oct 9

The recent read-out from the ODYSSEY phase 2b trial showed strong data, particularly at the 5-month re-dosing level, and flexible real-world re-dosing options, which are expected to positively impact the AMD market.
The solid Axitinib data from Clearside Biomedical's suprachoroidal delivery system is seen as a threat to competitors, particularly Oculentis, which uses an intravitreal delivery method.
Clearside Biomedical's data is expected to be a highlight at the upcoming AAO annual meeting on October 18, and the company has seen an increase in options trading activity, with investors acquiring 4,038 call options, a 1,327% increase from average daily volume.

Newcomers· Aug 7

Some users think CLSD's float can squeeze higher soon, with targets ranging from unknown to specific prices.
Others are unsure if it's too late to get in or if they should hold or cut losses if the stock stalls.
A few users are considering adding a small position in CLSD, but are uncertain about the risk-reward feel or if they should set a tight stop or ride the volatility.

Generated by AI

News

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection...

1mo agoBarchart.com

Clearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan Sponsor

NEW YORK, July 15, 2026--Clearside Biomedical, Inc. ("Clearside" or the "Company") today announced that it has completed its financial restructuring and emerged from Chapter 11. All conditions to the effectiveness of the Company’s plan of reorganization (the "Plan"), as confirmed by the United States Bankruptcy Court for the District of Delaware, have been satisfied or waived, and the Plan became effective on the closing date. The Plan was sponsored by Steel Partners, Ltd. ("Steel Partners"), wh

2mo agoYahoo Finance

Also Discussed

Investors talking about CLSD also mention

#	Name	Attention
1	Regenxbio Inc.RGNX	0%+0
2	Ocular Therapeutix, Inc.OCUL	0.02%-0.04
3	EyePoint, Inc. Common StockEYPT	0%0
4	4D Molecular Therapeutics, Inc.FDMT	0%new
5	ISEE - IVERIC bio, Inc.	——
6	APLS - Apellis Pharmaceuticals, Inc.	——
7	ADVM - Adverum Biotechnologies, Inc.	——
8	Aura Biosciences, Inc.AURA	0%0
9	Bausch + Lomb CorporationBLCO	0%0
10	WEBs Consumer Discretionary XLY Defined Volatility ETFDVXY	0%0

Clearside Biomedical Inc.

Healthcare
Biotechnology

Clearside Biomedical Inc. is a biopharmaceutical company focused on developing therapies for the treatment of eye diseases. The company specializes in utilizing its proprietary SCS Microinjector technology, which enables targeted drug delivery to the back of the eye by precisely reaching the suprachoroidal space. This technique is designed to improve the effectiveness of therapies while potentially reducing side effects. Clearside Biomedical's pipeline includes treatments for conditions like macular edema associated with uveitis, diabetic macular edema, and retinal vein occlusion. By addressing severe visual impairments and blindness, the company plays a crucial role in the ophthalmic pharmaceutical sector. Its innovations within ocular drug delivery methods are significant, shaping advances in how eye diseases are treated. As a key participant in the biopharmaceutical industry, Clearside Biomedical aims to meet the growing global demand for effective treatments with enhanced patient compliance and outcomes.

Website

Location

900 North Point Parkway

Alpharetta, GA, 30005

United States

Social

What share of all stock conversation is about CLSD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Aug 7

The float of Clearside Biomedical, Inc. (CLSD) is being considered for a potential squeeze, with some users wondering if it can move higher soon.
A few users are wondering if it's too late to get in on the stock, or if it's still a good time to buy.
Some users are debating whether to hold onto CLSD or cut losses if the stock stalls, with a few users wondering if a catalyst is needed to move the stock.

Generated by AI

Sentiment

Of the messages about CLSD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	59.93% -22.85
Bearish	—	—	—	40.07% +22.85

Bullish· Nov 24

$CLSD has a high potential for growth, with a target exit point of $10.
Clearside Biomedical, Inc. shareholders will receive all proceeds from the company's sale, net of $3m and legal fees, making a $10 per share price realistic.
The company's recent PR has unlocked a new future for $CLSD, with EU compliance at 47-50% presenting a large addressable gap and potential for significant growth.

Bearish· Jul 23

The company's management team is perceived as incompetent, unable to run a successful pump and dump.
The stock's price is vulnerable to a significant drop, potentially erasing all gains.
The company is likely to cease operations due to royalty obligations, with the possibility of asset sales or strategic alternatives.

Generated by AI

Topics

Of the messages about CLSD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	31.77%
Announcements	—	—	—	39.35%
Controversies	—	—	—	1.08%
Earnings	—	—	—	0%
Macro	—	—	—	27.8%
Technical Analysis	—	—	—	0%

Earnings· May 9

Clearside Biomedical, Inc. (CLSD) reported a loss of $0.62, missing EPS estimates by $0.04.
CLSD will host a Q1 Earnings Call on the day of earnings release, May 9th, before the open.
CLSD's Q1 earnings were released on May 9th, showing a loss of $0.62, which missed consensus estimates.

Announcements· Nov 24

Clearside Biomedical, Inc. (CLSD) has filed a voluntary petition for bankruptcy protection through a Chapter 11 process.
The company plans to pursue a strategic sale of its business through this process.
CLSD shares are trading lower following the announcement, with the company's shares being affected by the bankruptcy filing.

Technical Analysis· Jun 15

$CLSD is holding near the day high on a support line, with potential for further upside.
A cup and handle formation is visible on the daily chart, suggesting a potential continuation of the uptrend.
The stock has a hidden bullish divergence, with lower lows and higher highs, indicating a possible shift in trend.

Generated by AI

Community

Of the messages about CLSD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	65.33%
Newcomers	—	—	100%	34.67%

Regulars· Oct 9

The recent read-out from the ODYSSEY phase 2b trial showed strong data, particularly at the 5-month re-dosing level, and flexible real-world re-dosing options, which are expected to positively impact the AMD market.
The solid Axitinib data from Clearside Biomedical's suprachoroidal delivery system is seen as a threat to competitors, particularly Oculentis, which uses an intravitreal delivery method.
Clearside Biomedical's data is expected to be a highlight at the upcoming AAO annual meeting on October 18, and the company has seen an increase in options trading activity, with investors acquiring 4,038 call options, a 1,327% increase from average daily volume.

Newcomers· Aug 7

Some users think CLSD's float can squeeze higher soon, with targets ranging from unknown to specific prices.
Others are unsure if it's too late to get in or if they should hold or cut losses if the stock stalls.
A few users are considering adding a small position in CLSD, but are uncertain about the risk-reward feel or if they should set a tight stop or ride the volatility.

Generated by AI

Clearside Biomedical

Social

Aug 7

Bullish· Nov 24

Bearish· Jul 23

Earnings· May 9

Announcements· Nov 24

Technical Analysis· Jun 15

Regulars· Oct 9

Newcomers· Aug 7

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

Clearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan Sponsor

Also Discussed

Clearside Biomedical Inc.

Company Information

Location

Social

Aug 7

Bullish· Nov 24

Bearish· Jul 23

Earnings· May 9

Announcements· Nov 24

Technical Analysis· Jun 15

Regulars· Oct 9

Newcomers· Aug 7

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

Clearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan Sponsor

Also Discussed